TRPA1 and neuropathy: In particular, we used the paclitaxel-induced animal model, because this chemotherapeutic agent is widely recognized to cause mechanical hypersensitivity owing to oxidative stress and TRPA1-dependent neuropathy.48,57 Systemic injections of paclitaxel (PAX, 2 mg/kg, two injections administered every other day) induced prolonged mechanical hypersensitivity in wild-type mice, which subsided after 14 days.58,59 Notably, this hypersensitivity was not observed in mice lacking TRPA1 (i.e. Trpa1−/−) expression.